Diligence memo · auto-generated · as of July 2, 2026

Hyalex Orthopaedics, Inc.

Hyalex Orthopaedics, Inc. looks under-valued against its niche peers and is quiet on financing cadence.

SourceModeled below same-niche peers while still financing on rhythm — a potential mispricing worth a closer look.

Businessfiled

Hyalex Orthopaedics, Inc. operates in Other Health Care, based in LEXINGTON.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Hyalex Orthopaedics, Inc. has raised $30M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $31M on 2017-05-16.

Most recent recorded round closed around 2024-09-17.

Valuation (modeled)modeled

Provath models Hyalex Orthopaedics, Inc. at approximately $91M (range $35M–$157M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.60× the median modeled value of Series B Other Health Care companies in 2022–2024 (91 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 29 months.

Last raise 21 mo ago; this sector typically re-raises about every 14 months.

Slightly overdue versus sector cadence.

The last round was 1.0× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 88% of Other Health Care peers (5377 compared).

Modeled value ranks above 77% of those peers.

Closest niche peers: Code Biotherapeutics, Inc., Candesant Biomedical, Inc., Artis Holdings, LLC, GIO Blood Ltd, Clarapath, Inc..

Peoplefiled

14 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.